Array Biopharma’s Braftovi triple therapy meets both endpoints in advanced colorectal cancer subtype
pharmafile | May 22, 2019 | News story | Research and Development | Array Biopharma, Braftovi, Cancer, colorectal cancer, pharma
Array Biopharma has revealed new data on its combination of Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab), showing that it met both of its primary endpoints in the treatment of BRAFV600E-mutant metastatic colorectal cancer (mCRC), in patients who have received one or two prior lines of therapy.
The data showed that patients receiving the triplet combo showed “statistically significant improvement” in objective response, with rates of 26.1% compared to 1.9% with cetuximab plus irinotecan-containing regimens. Additionally, the combo also improved overall survival by a median 9.0 months compared to 5.4 months.
“The Beacon CRC trial is the first Phase 3 trial in patients with BRAFV600E-mutant mCRC and these results show a significant improvement compared to available standard of care options for this patient population,” said Dr Scott Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. “Given that there are no therapies currently FDA-approved for this patient population, I believe the results of the Beacon CRC trial will be practice-changing.”
Ron Squarer, CEO of Array BioPharma, also remarked: “We are pleased to announce positive results from the Beacon CRC trial, including that the Braftovi Triplet reduced the risk of death by 48% versus control. We are deeply grateful to the patients and investigators whose participation has helped bring us one step closer to delivering a new standard of care for patients with BRAF-mutant mCRC. This has the potential to be the first chemotherapy-free, targeted regimen for mCRC patients, a population with a very high unmet need for effective treatments.”
Array confirmed that it intends to submit these data in its marketing applications in the second half of the year.
Matt Fellows
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
Ryvu Therapeutics publishes research revealing potential drug combination for colorectal cancer
Ryvu Therapeutics has published new findings from its ONCO Prime target discovery platform in Scientific …
